(January 30, 2024, 11:09 AM EST) -- ALEXANDRIA, Va. — A “copycat” challenge to a patent associated with the weight loss drug Ozempic filed 18 months after the petitioners were accused of infringement — and that seeks joinder to an existing and timely inter partes review (IPR) initiated by Mylan Pharmaceuticals Inc. — falls outside the time limits proscribed in federal patent law, Novo Nordisk A/S tells the Patent Trial and Appeal Board....